Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2017

Open Access 01-12-2017 | Research

Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles

Authors: Kevin C. Kobylinski, Ratawan Ubalee, Alongkot Ponlawat, Chanyapat Nitatsukprasert, Siriporn Phasomkulsolsil, Thanaporn Wattanakul, Joel Tarning, Kesara Na-Bangchang, Patrick W. McCardle, Silas A. Davidson, Jason H. Richardson

Published in: Malaria Journal | Issue 1/2017

Login to get access

Abstract

Background

Novel vector control methods that can directly target outdoor malaria transmission are urgently needed in the Greater Mekong Subregion (GMS) to accelerate malaria elimination and artemisinin resistance containment efforts. Ivermectin mass drug administration (MDA) to humans has been shown to effectively kill wild Anopheles and suppress malaria transmission in West Africa. Preliminary laboratory investigations were performed to determine ivermectin susceptibility and sporontocidal effect in GMS Anopheles malaria vectors coupled with pharmacokinetic models of ivermectin at escalating doses.

Methods

A population-based pharmacokinetic model of ivermectin was developed using pre-existing data from a clinical trial conducted in Thai volunteers at the 200 µg/kg dose. To assess ivermectin susceptibility, various concentrations of ivermectin compound were mixed in human blood meals and blood-fed to Anopheles dirus, Anopheles minimus, Anopheles sawadwongporni, and Anopheles campestris. Mosquito survival was monitored daily for 7 days and a non-linear mixed effects model with probit analyses was used to calculate concentrations of ivermectin that killed 50% (LC50) of mosquitoes for each species. Blood samples were collected from Plasmodium vivax positive patients and offered to mosquitoes with or without ivermectin at the ivermectin LC25 or LC5 for An. dirus and An. minimus.

Results

The GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC50 = 16.3 ng/ml) > An. campestris (LC50 = 26.4 ng/ml) = An. sawadwongporni (LC50 = 26.9 ng/ml) > An. dirus (LC50 = 55.6 ng/ml). Mosquito survivorship results, the pharmacokinetic model, and extensive safety data indicated that ivermectin 400 µg/kg is the ideal minimal dose for MDA in the GMS for malaria parasite transmission control. Ivermectin compound was sporontocidal to P. vivax in both An. dirus and An. minimus at the LC25 and LC5 concentrations.

Conclusions

Ivermectin is lethal to dominant GMS Anopheles malaria vectors and inhibits sporogony of P. vivax at safe human relevant concentrations. The data suggest that ivermectin MDA has potential in the GMS as a vector and transmission blocking control tool to aid malaria elimination efforts.
Appendix
Available only for authorised users
Literature
1.
von Seidlein L, Dondorp A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti Infect Ther. 2015;13:715–30.CrossRef
2.
Van Bortel W, Trung H, Hoi L, Ham N, Chut N, Luu N, et al. Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control. Malar J. 2010;9:373.CrossRefPubMedPubMedCentral
3.
Trung H, van Bortel W, Sochantha T, Keokenchanh K, Briët O, Coosemans M. Behavioural heterogeneity of Anopheles species in ecologically different localities in Southeast Asia: a challenge for vector control. Trop Med Int Health. 2005;10:251–62.CrossRefPubMed
4.
Chaccour C, Rabinovich N, Slater H, Canavati S, Bousema T, Lacerda M, et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J. 2015;14:243.CrossRefPubMedPubMedCentral
5.
Kobylinski K, Deus K, Butters M, Hongyu T, Gray M, da Silva I, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119–25.CrossRefPubMedPubMedCentral
6.
Fritz M, Siegert P, Walker E, Bayoh M, Vulule J, Miller J. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103:539–47.CrossRefPubMed
7.
Chaccour C, Lines J, Whitty C. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113–6.CrossRefPubMed
8.
Ouédraogo A, Bastiaens G, Tiono A, Guelbéogo W, Kobylinski K, Ouédraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60:357–65.CrossRefPubMed
9.
Derua Y, Kisinza W, Simonsen P. Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasites Vectors. 2015;8:130.CrossRefPubMedPubMedCentral
10.
Sylla M, Kobylinski K, Gray M, Chapman P, Sarr M, Rasgon J, Foy B. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.CrossRefPubMedPubMedCentral
11.
Alout H, Krajacich B, Meyers J, Grubaugh N, Brackney D, Kobylinski K, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13:417.CrossRefPubMedPubMedCentral
12.
Kobylinski K, Sylla M, Chapman P, Sarr M, Foy B. Short report: ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3–5.CrossRefPubMedPubMedCentral
13.
14.
Kobylinski K, Alout H, Foy B, Clements A, Adisakwattana P, Swierczewski B, Richardson J. Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. Am J Trop Med Hyg. 2014;91:655–62.CrossRefPubMedPubMedCentral
15.
16.
Tisgratog R, Tananchai C, Juntarajumnong W, Tuntakom S, Bangs M, Corbel V, Chareonviriyaphap T. Host feeding patterns and preference of Anopheles minimus (Diptera: Culicidae) in a malaria endemic area of western Thailand: baseline site description. Parasites Vectors. 2012;5:114.CrossRefPubMedPubMedCentral
17.
Rattanarithikul R, Konishi E, Linthicum K. Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. Am J Trop Med Hyg. 1996;54:114–21.CrossRefPubMed
18.
Thongsahuan S, Baimai V, Junkum A, Saeung A, Min G, Joshi D, et al. Susceptibility of Anopheles campestris-like and Anopheles barbirostris species complexes to Plasmodium falciparum and Plasmodium vivax in Thailand. Mem Inst Oswaldo Cruz. 2011;106:105–12.CrossRefPubMed
19.
Guzzo C, Furtek C, Porras A, Chen C, Tipping R, Clineschmidt C, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42:1122–33.CrossRefPubMed
20.
Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis. 2011;5:1044.CrossRef
21.
Awadzi K, Opoku N, Addy E, Quartey B. The chemotherapy of onchocerciasis. XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol. 1995;46:131–7.PubMed
22.
Awadzi K, Attah S, Addy E, Opoku N, Quartey B. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg. 1999;93:189–94.CrossRefPubMed
23.
Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Duke BO. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360:203–10.CrossRefPubMed
24.
Na-Bangchang K, Kietinun S, Pawa K, Hanpitakpong W, Na-Bangchang C, Lazdins J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans R Soc Trop Med Hyg. 2006;100:335–45.CrossRefPubMed
25.
Jonsson E, Karlsson M. Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;8:51–64.
26.
Keizer R, van Benten M, Beijnen J, Schellens J, Huitema A. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–9.CrossRefPubMed
27.
Lindbom L, Ribbing J, Jonsson E. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.CrossRefPubMed
28.
Macey R, Oster G, Zahnley T, Gittelsohn M. Berkeley Madonna. Berkeley. 2000.
29.
Phasomkusolsil S, Pantuwattana K, Tawong J, Khongtak W, Kertmanee Y, Monkanna N, et al. The relationship between wing length, blood meal volume, and fecundity for seven colonies of Anopheles species housed at the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. Acta Trop. 2015;152:220–7.CrossRefPubMed
30.
Sattabongkot J, Maneechai N, Phunkitchar V, Eikarat N, Khuntirat B, Sirichaisinthop J, et al. Comparison of artificial membrane feeding with direct skin feeding to estimate the infectiousness of Plasmodium vivax gametocyte carriers to mosquitoes. Am J Trop Med Hyg. 2003;69:529–35.PubMed
31.
Tainchum K, Kongmee M, Manguin S, Bangs M, Chareonviriyaphap T. Anopheles species diversity and distribution of the malaria vectors of Thailand. Trends Parasitol. 2015;31:109–19.CrossRefPubMed
32.
Zeng Z, Andrew N, Arison B, Luffer-Atlas D, Wang R. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998;28:313–21.CrossRefPubMed
33.
34.
Bellinger A, Jafari M, Grant T, Zhang S, Slater H, Wegner E, et al. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2016;8:157.CrossRef
35.
Chaccour C, Barrio Á, Royo AG, Urbistondo DM, Slater H, Hammann F, Del Pozo J. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J. 2015;14:102.CrossRefPubMedPubMedCentral
36.
Chaccour C, Abizanda G, Irigoyen Á, Del Pozo J. Pilot study of a slow-release ivermectin formulation for malaria control in a pig model. Antimicrob Agents Chemother. 2017;61:02104–16.CrossRef
37.
Baraka O, Mahmoud B, Marschke C, Geary T, Homeida M, Williams J. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407–10.CrossRefPubMed
38.
El-Tahtawy A, Glue P, Andrews E, Mardekian J, Amsden G, Knirsch C. The effect of azithromycin on ivermectin pharmacokinetics—a population pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008;2:236.CrossRef
39.
40.
Anderson B, Holford N. Mechanism-based concepts of size and maturity in pharmacokinetics. Ann Rev Pharmacol Toxicol. 2008;48:303–32.CrossRef
41.
Smit M, Ochomo E, Aljayyoussi G, Kwambai T, Abong’o B, Bayoh N, et al. Efficacy and safety of high-dose ivermectin for reducing malaria transmission (IVERMAL): protocol for a double-blind, randomized, placebo-controlled, dose-finding trial in Western Kenya. JMIR Res Protoc. 2016;5:213.CrossRef
42.
Ramaiah K, Das P, Vanamail P, Pani S. Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis. Trans R Soc Trop Med Hyg. 2007;101:555–63.CrossRefPubMed
43.
Cooper P, Awadzi K, Ottesen E, Remick D, Nutman T. Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin. J Infect Dis. 1999;179:738–42.CrossRefPubMed
44.
Martin-Prevel Y, Cosnefroy J, Tshipamba P, Ngari P, Chodakewitz J, Pinder M. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg. 1993;48:186–92.CrossRefPubMed
45.
Ismail M, Weil G, Jayasinghe K, Premaratne U, Abeyewickreme W, Rajaratnam H, et al. Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine. Trans R Soc Trop Med Hyg. 1996;90:684–8.CrossRefPubMed
46.
Ismail M, Jayakody R, Weil G, Nimalan N, Jayasinghe K, Abeyewickrema W, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg. 1998;92:94–7.CrossRefPubMed
47.
Ismail M, Jayakody R, Weil G, Fernando D, de Silva G, Balasooriya W. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg. 2001;95:332–5.CrossRefPubMed
48.
Dembele B, Coulibaly Y, Dolo H, Konate S, Coulibaly S, Sanogo D, et al. Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. Clin Infect Dis. 2010;51:1229–35.CrossRefPubMedPubMedCentral
49.
Bockarie M, Alexander N, Hyun P, Dimber Z, Bockarie F, Ibam E, et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet. 1998;351:162–8.CrossRefPubMed
50.
Kazura J, Greenberg J, Perry R, Weil G, Day K, Alpers M. Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. Am J Trop Med Hyg. 1993;49:804–11.CrossRefPubMed
51.
Cartel J, Moulia-Pelat J, Glaziou P, Nguyen L, Chanteau S, Roux J. Results of a safety trial on single-dose treatments with 400 mcg/kg of ivermectin in bancroftian filariasis. Trop Med Parasitol. 1992;43:263–6.PubMed
52.
Glaziou P, Moulia-Pelat J, Nguyen L, Chanteau S, Martin P, Cartel J. Double-blind controlled trial of a single dose of the combination ivermectin 400 micrograms/kg plus diethylcarbamazine 6 mg/kg for the treatment of bancroftian filariasis: results at six months. Trans R Soc Trop Med Hyg. 1994;88:707–8.CrossRefPubMed
53.
Moulia-Pelat J, Glaziou P, Nguyen L, Chanteau S, Pilchart R, Beylier I, et al. Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in bancroftian filariasis. Trans R Soc Trop Med Hyg. 1994;88:107–9.CrossRefPubMed
54.
Moulia-Pelat J, Nguyen L, Glaziou P, Chanteau S, Ottesen E, Cardines R, et al. Ivermectin plus diethylcarbamazine: an additive effect on early microfilarial clearance. Am J Trop Med Hyg. 1994;50:206–9.CrossRefPubMed
55.
Moulia-Pelat J, Glaziou P, Nguyen L, Cartel J. Single doses of ivermectin 400 micrograms/kg: the most effective dosage in bancroftian filariasis. Southeast Asian J Trop Med Public Health. 1995;26:124–7.PubMed
56.
Nguyen L, Moulia-Pelat J, Cartel J. Control of bancroftian filariasis in an endemic area of Polynesia by ivermectin 400 micrograms/kg. Trans R Soc Trop Med Hyg. 1996;90:689–91.CrossRefPubMed
57.
Nguyen L, Moulia-Pelat J, Glaziou P, Martin P, Cartel J. Advantages of ivermectin at a single dose of 400 micrograms/kg compared with 100 micrograms/kg for community treatment of lymphatic filariasis in Polynesia. Trans R Soc Trop Med Hyg. 1994;88:461–4.CrossRefPubMed
58.
Moulia-Pelat J, Nguyen L, Hascoёt H, Nicolas L. Combinations of ivermectin and diethylcarbamazine for improved control of lymphatic filariasis. Parasite. 1996;3:45–8.CrossRefPubMed
59.
Dreyer G, Coutinho A, Miranda D, Norões J, Rizzo J, Galdino E, et al. Treatment of bancroftian filariasis in Recife, Brazil: a two-year comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine. Trans R Soc Trop Med Hyg. 1995;89:98–102.CrossRefPubMed
60.
Dreyer G, Norões J, Amaral F, Nen A, Medeiros Z, Coutinho A, Addiss D. Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariasis. Trans R Soc Trop Med Hyg. 1995;89:441–3.CrossRefPubMed
61.
Dreyer G, Addiss D, Norões J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. Trop Med Int Health. 1996;1:427–32.CrossRefPubMed
62.
Dreyer G, Addiss D, Santos A, Figueredo-Silva J, Norões J. Direct assessment in vivo of the efficacy of combined single-dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg. 1998;92:219–22.CrossRefPubMed
63.
Addiss D, Eberhard M, Lammie P, McNeeley M, Lee S, McNeeley D, Spencer H. Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia. Am J Trop Med Hyg. 1993;48:178–85.CrossRefPubMed
64.
Addiss D, Beach M, Streit T, Lutwick S, LeConte F, Lafontant J, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet. 1997;350:480–4.CrossRefPubMed
65.
Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann S, Burgess I. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010;362:896–905.CrossRefPubMed
66.
67.
Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377–410.CrossRefPubMedPubMedCentral
68.
Pooda H, Rayaisse J-B, de Sale Hien D, Lefèvre T, Yerbanga S, Bengaly Z, et al. Administration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria. Malar J. 2015;14:496.CrossRefPubMedCentral
69.
Mahmood F, Walters L, Guzman H, Tesh R. Effect of ivermectin on the ovarian development of Aedes aegypti (Diptera: Culicidae). J Med Entomol. 1991;28:701–7.CrossRefPubMed
70.
Seaman J, Alout H, Meyers J, Stenglein M, Dabiré R, Lozano-Fuentes S, et al. Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals. Malar J. 2015;16:797.
71.
Alout H, Foy B. Ivermectin: a complimentary weapon against the spread of malaria? Expert Rev Anti Infect Ther. 2017;15:231–40.CrossRefPubMed
72.
Cirimotich C, Dong Y, Clayton AM, Sandiford SL, Souza-Neto JA, Mulenga M, Dimopoulos G. Natural microbe-mediated refractoriness to Plasmodium infection in Anopheles gambiae. Science. 2011;332:855–8.CrossRefPubMedPubMedCentral
73.
Burg R, Stapley E. Isolation and characterization of the producing organism. In: Campbell WC, editor. Ivermectin and abamectin. New York: Springer; 1989. p. 24–32.CrossRef
74.
Guo H, Ren B, Dai H, Dai S, Zhang Y, Liu Y, Cao B, Zhang L. Reversal of meticillin resistance in Staphylococcus aureus by the anthelmintic avermectin. Int J Antimicrob Agents. 2014;44:274–6.CrossRefPubMed
75.
Pettengill M, Lam V, Ollawa I, Marques-da-Silva C, Ojcius D. Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells. PLoS ONE. 2012;7:48456.CrossRef
76.
Lim L, Vilchèze C, Ng C, Jacobs WJ, Ramón-García S, Thompson C. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother. 2013;57:1040–6.CrossRefPubMedPubMedCentral
77.
Rodgers F, Gendrin M, Wyer C, Christophides G. Microbiota-induced peritrophic matrix regulates midgut homeostasis and prevents systemic infection of malaria vector mosquitoes. PLoS Pathog. 2017;13:1006391.CrossRef
78.
Hotez P, Bottazzi M, Strych U, Chang L, Lim Y, Goodenow M, AbuBakar S. Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update. PLoS Negl Trop Dis. 2015;9:0003575.
79.
Khieu V, Schär F, Forrer A, Hattendorf J, Marti H, Duong S, et al. High prevalence and spatial distribution of Strongyloides stercoralis in rural Cambodia. PLoS Negl Trop Dis. 2014;8:2854.CrossRef
80.
Vonghachack Y, Sayasone S, Bouakhasith D, Taisayavong K, Akkavong K, Odermatt P. Epidemiology of Strongyloides stercoralis on Mekong islands in southern Laos. Acta Trop. 2015;141:289–94.CrossRefPubMed
81.
Khieu V, Hattendorf J, Schär F, Marti H, Char M, Muth S, Odermatt P. Strongyloides stercoralis infection and re-infection in a cohort of children in Cambodia. Parasitol Int. 2014;63:708–12.CrossRefPubMed
82.
Okeibunor J, Amuyunzu-Nyamongo M, Onyeneho N, Tchounkeu Y, Manianga C, Kabali A, Leak S. Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa. Trop Med Int Health. 2011;16:608–21.CrossRefPubMed
83.
Eisele T, Bennett A, Silumbe K, Finn T, Chalwe V, Kamuliwo M, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214:1831–9.CrossRefPubMedPubMedCentral
84.
Slater H, Walker P, Bousema T, Okell L, Ghani A. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972–80.CrossRefPubMed
Metadata
Title
Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles
Authors
Kevin C. Kobylinski
Ratawan Ubalee
Alongkot Ponlawat
Chanyapat Nitatsukprasert
Siriporn Phasomkulsolsil
Thanaporn Wattanakul
Joel Tarning
Kesara Na-Bangchang
Patrick W. McCardle
Silas A. Davidson
Jason H. Richardson
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2017
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-017-1923-8

Other articles of this Issue 1/2017

Malaria Journal 1/2017 Go to the issue

Research

Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

Research

Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors

Research

Host-seeking activity of a Tanzanian population of Anopheles arabiensis at an insecticide treated bed net

Research

A village level cluster-randomized entomological evaluation of combination long-lasting insecticidal nets containing pyrethroid plus PBO synergist in Southern Mali

Research

Evaluation of the Deki Reader™, an automated RDT reader and data management device, in a household survey setting in low malaria endemic southwestern Uganda

Research

Clinical and molecular surveillance of drug resistant vivax malaria in Myanmar (2009–2016)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits